Results 1 to 10 of about 47 (43)

Erythropoietin messenger RNA levels in developing mice and transfer of 125I-erythropoietin by the placenta. [PDF]

Journal of Clinical Investigation, 1988
Erythropoietin (EP) mRNA was measured in normal and anemic mice during fetal and postnatal development. Normal fetal livers at 14 d of gestation contained a low level of EP mRNA. By day 19 of gestation, no EP mRNA was detected in normal or anemic fetal livers or normal fetal kidneys, but anemic fetal kidneys had low levels of EP mRNA.
M J Koury, S T Sawyer
exaly   +3 more sources

Synthesis and biological evaluation of 125I-erythropoietin as a potential radiopharmaceutical agent for tumours

Brazilian Journal of Pharmaceutical Sciences, 2011
Erythropoietin (EPO) is a glycoprotein hormone responsible for regulating erythropoiesis. Expression of EPO and EPO receptors (EPOr) has recently been demonstrated in some neoplastic cell lines and tumours, suggesting a potential new target for therapy ...
Gonçalo dos Santos Clemente, Vera Lúcia Serra Duarte   +1 more
doaj   +5 more sources

The Concise Guide to PHARMACOLOGY 2023/24: Catalytic receptors

British Journal of Pharmacology, Volume 180, Issue S2, Page S241-S288, October 2023., 2023
The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and nearly 6000 interactions with about 3900 ligands.
Stephen P. H. Alexander, Doriano Fabbro, Eamonn Kelly, Alistair A. Mathie, John A. Peters, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Jamie A. Davies, Annie Beuve, Peter Brouckaert, Clare Bryant, John C. Burnett, Richard W. Farndale, Andreas Friebe, John Garthwaite, Adrian J. Hobbs, Gavin E. Jarvis, Doris Koesling, Michaela Kuhn, David MacEwan, Tom P. Monie, Lincoln R. Potter, Michael Russwurm, Harald H. H. W. Schmidt, Johannes‐Peter Stasch, Scott A. Waldman   +27 more
wiley   +1 more source

Independent risk factors of rapid glomerular filtration rate decline in patients with type 2 diabetes with preserved kidney function and normoalbuminuria: A multicenter cohort study

Journal of Diabetes Investigation, Volume 14, Issue 7, Page 874-882, July 2023., 2023
We conducted a retrospective cohort study of patients with type 2 diabetes with preserved renal function and normoalbuminuria, with and without rapid decliners, to investigate the involvement of the baseline hemoglobin level as a potential predictor of rapid renal function decline.
Daishi Hirano, Hiroyuki Unoki‐Kubota, Toshiyuki Imasawa, Ritsuko Yamamoto‐Honda, Hiroshi Kajio, Shigeo Yamashita, Yuka Fukazawa, Naoto Seki, Mitsuhiko Noda, Yasushi Kaburagi   +9 more
wiley   +1 more source

Validation of a clinically applicable device for fast and accurate quantification of blood volume

Journal of Clinical Laboratory Analysis, Volume 37, Issue 9-10, May 2023., 2023
The cumbersome nature of the dual‐isotope (e.g., 99mTc and 125I‐HSA) injection method has limited the widespread use of blood volume (BV) evaluation in medicine. However, BV has been determined in laboratory settings for centuries using a reliable and rapid carbon monoxide (CO)‐rebreathing‐based procedure.
Andreas Breenfeldt Andersen, Thomas C. Bonne, Joar Hansen, Peter Oturai, Carsten Lundby   +4 more
wiley   +1 more source

Maternal melatonin: Effective intervention against developmental programming of cardiovascular dysfunction in adult offspring of complicated pregnancy

Journal of Pineal Research, Volume 72, Issue 1, January 2022., 2022
Abstract Adopting an integrative approach, by combining studies of cardiovascular function with those at cellular and molecular levels, this study investigated whether maternal treatment with melatonin protects against programmed cardiovascular dysfunction in the offspring using an established rodent model of hypoxic pregnancy. Wistar rats were divided
Jeremy A. Hansell, Hans G. Richter, Emily J. Camm, Emilio A. Herrera, Carlos E. Blanco, Eduardo Villamor, Olga V. Patey, Mitchell C. Lock, Andrew W. Trafford, Gina L. J. Galli, Dino A. Giussani   +10 more
wiley   +1 more source

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Catalytic receptors

British Journal of Pharmacology, Volume 178, Issue S1, Page S264-S312, October 2021., 2021
The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets ...
Stephen P H Alexander, Doriano Fabbro, Eamonn Kelly, Alistair Mathie, John A Peters, Emma L Veale, Jane F Armstrong, Elena Faccenda, Simon D Harding, Adam J Pawson, Christopher Southan, Jamie A Davies, Annie Beuve, Peter Brouckaert, Clare Bryant, John C. Burnett, Richard W. Farndale, Andreas Friebe, John Garthwaite, Adrian J. Hobbs, Gavin E. Jarvis, Michaela Kuhn, David MacEwan, Tom P. Monie, Lincoln R. Potter, Harald H.H.W. Schmidt, Scott A. Waldman   +26 more
wiley   +1 more source

Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin

Diabetes, Obesity and Metabolism, Volume 23, Issue 7, Page 1660-1665, July 2021., 2021
Abstract Sodium‐glucose cotransporter‐2 inhibitors (SGLT2) are drugs that have been reported to have several effects through the regulation of plasma volume, for example, antihypertensive effects. This study aimed to clarify the impact of long‐term administration and subsequent discontinuation of the SGLT2 inhibitor tofogliflozin on estimated plasma ...
Yasuhiro Matsubayashi, Akihiro Yoshida, Hideki Suganami, Momoko Oe, Takaaki Sato, Yuta Yaguchi, Kazuya Fujihara, Takaho Yamada, Shiro Tanaka, Kohei Kaku, Hirohito Sone   +10 more
wiley   +1 more source

Erythropoietin promoted the proliferation of hepatocellular carcinoma through hypoxia induced translocation of its specific receptor

Cancer Cell International, 2017
Background Erythropoietin (EPO) is a hypoxia-inducible stimulator of erythropoiesis. Besides its traditional application in anemia therapy, it offers an effective treatment in the cancer patients, especially those who receive chemotherapy.
Shuo Miao, Su-Mei Wang, Xue Cheng, Yao-Feng Li, Qing-Song Zhang, Gang Li, Song-Qing He, Xiao-Ping Chen, Ping Wu   +8 more
doaj   +1 more source

Abstract

, 2022
Research and Practice in Thrombosis and Haemostasis, Volume 6, Issue S1, October 2022.
wiley   +1 more source